Please assess the completion status of the following clinical trial:

Trial Title: Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Normal healthy infants of age 15-18 months at the time of the screening and have not received their first dose of MMR vaccine.~2. Previously received a measles monovalent vaccine at 9 months, as confirmed by the childhood vaccination record.~3. Parents or legal guardians of subject willing to give written informed consent and willing to comply with study protocol.~4. Free of obvious health problems as established by medical history and screening evaluation including clinical examination.~Exclusion Criteria:~1. Infant subject participating in other clinical trial or planned participation in another clinical trial during the present trial period~2. Infant with congenital or acquired immunodeficiency, malignancy or receiving immunosuppressive therapy.~3. Infant with history of allergy or systemic hypersensitivity to any of the vaccine component or to a vaccine containing the same substances.~4. Infant with history of epilepsy or a seizure disorder or neurodevelopmental disorders.~5. Clinical history of measles, mumps, or rubella infection.~6. Infants with leukemia, lymphoma, or any other cancer or neoplasm.~7. Acute or chronic, clinically significant pulmonary, endocrine, autoimmune, neurological, cardiovascular, metabolic, hepatic or renal functional abnormality, as determined by medical history, and physical examination tests, which in the opinion of the investigator, might interfere with the study objectives~8. Infant with any other condition, which, in the opinion of the investigator would jeopardize the safety or rights of the infant participating in the study or making it unlikely the subject could complete the protocol.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Disposable syringe jet injector (Type: EXPERIMENTAL): Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc.
- Needle-Syringe (Type: ACTIVE_COMPARATOR): Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via conventional needle and Syringe

Based on this trial design, predict the completion outcome and termination type (if applicable).